Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | EYA2 | O00167 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8047064 | 0.96 | TSHR (0.52) | TDP1EYA2APPACETSHR | |
| SCHEMBL10002229 | 0.88 | KDM4E (0.45) | TDP1EYA2APPACETSHR | |
| Edetic Acid SCHEMBL9299364 | 0.84 | TDP1 (0.52) | TDP1EYA2APPACETSHR | |
| SCHEMBL5157765 | 0.84 | KDM4E (0.55) | TSHRADRA1AKDM4EBLMMTNR1A | |
| SCHEMBL18307272 | 0.82 | KDM4E (0.48) | TSHRADRA1AKDM4EBLMMTNR1A | |
| SCHEMBL16790905 | 0.81 | KDM4E (0.52) | TSHRADRA1AKDM4EBLMMTNR1A | |
| SCHEMBL14586734 | 0.81 | BLM (0.49) | TDP1EYA2APPACETSHR | |
| SCHEMBL19059678 | 0.79 | ADRA1A (0.47) | TDP1EYA2APPACETSHR | |
| SCHEMBL474091 | 0.77 | ALDH1A1 (0.53) | TSHRKDM4EBLMPMP22LMNA | |
| SCHEMBL13231974 | 0.77 | TDP1 (0.59) | TDP1EYA2APPACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3391876-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1883395-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127360-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | TDP1 4728/4885EYA2 4439/4885APP 2093/4885 |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885EYA2 4204/4885APP 747/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885EYA2 4704/4885APP 531/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885EYA2 4204/4885APP 747/4885 |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885EYA2 3910/4885APP 400/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885EYA2 4204/4885APP 747/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | TDP1 4815/4885EYA2 3580/4885APP 915/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4757/4885EYA2 4447/4885APP 654/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885EYA2 3910/4885APP 400/4885 |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | TDP1 4882/4885EYA2 3910/4885APP 400/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885EYA2 4204/4885APP 747/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | TDP1 4863/4885EYA2 4188/4885APP 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.